Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954236 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
A Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03954236: Active Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03954236 is a Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03954236, a Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
Primary Outcome
The difference in BSA of non-sclerotic cutaneous cGVHD between ruxolitinib treated side and vehicle treated sides of the face/body at study completion
Conditions Studied
Interventions
- DRUG topical ruxolitinib 1.5% cream
- OTHER Topical vehicle/moisturizer cream
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2027-02-06 |
| Phase | Phase 2 |
What the registry record for NCT03954236 still lists
NCT03954236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Non-sclerotic Cutaneous Chronic Graft-versus-host Disease appearing as the primary indexed condition, and to 2 interventions - of which topical ruxolitinib 1.5% cream is the first listed.
NCT03954236 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03954236 about?
NCT03954236 is a clinical study titled "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease". The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
What is the current status of trial NCT03954236?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-05-14. Estimated completion is 2027-02-06.
What conditions does trial NCT03954236 study?
This clinical trial studies the following conditions: Non-sclerotic Cutaneous Chronic Graft-versus-host Disease.
What interventions are being tested in trial NCT03954236?
The interventions under investigation include: topical ruxolitinib 1.5% cream (DRUG), Topical vehicle/moisturizer cream (OTHER).
Who is sponsoring clinical trial NCT03954236?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03954236 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03954236's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI